Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

897 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.
Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrié P. Alonso R, et al. Mol Psychiatry. 2004 Mar;9(3):278-86, 224. doi: 10.1038/sj.mp.4001464. Mol Psychiatry. 2004. PMID: 14699428
SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization.
Steinberg R, Alonso R, Rouquier L, Desvignes C, Michaud JC, Cudennec A, Jung M, Simiand J, Griebel G, Emonds-Alt X, Le Fur G, Soubrié P. Steinberg R, et al. Among authors: alonso r. J Pharmacol Exp Ther. 2002 Dec;303(3):1180-8. doi: 10.1124/jpet.102.040279. J Pharmacol Exp Ther. 2002. PMID: 12438542
SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization.
Gougat J, Ferrari B, Sarran L, Planchenault C, Poncelet M, Maruani J, Alonso R, Cudennec A, Croci T, Guagnini F, Urban-Szabo K, Martinolle JP, Soubrié P, Finance O, Le Fur G. Gougat J, et al. Among authors: alonso r. J Pharmacol Exp Ther. 2004 May;309(2):661-9. doi: 10.1124/jpet.103.059527. Epub 2004 Jan 27. J Pharmacol Exp Ther. 2004. PMID: 14747609
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
Depoortère R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, Cudennec A, Voltz C, Boulay D, Terranova JP, Stemmelin J, Roger P, Marabout B, Sevrin M, Vigé X, Biton B, Steinberg R, Françon D, Alonso R, Avenet P, Oury-Donat F, Perrault G, Griebel G, George P, Soubrié P, Scatton B. Depoortère R, et al. Among authors: alonso r. Neuropsychopharmacology. 2005 Nov;30(11):1963-85. doi: 10.1038/sj.npp.1300772. Neuropsychopharmacology. 2005. PMID: 15956994
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.
Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G. Stemmelin J, et al. Among authors: alonso r. Neuropsychopharmacology. 2008 Feb;33(3):574-87. doi: 10.1038/sj.npp.1301424. Epub 2007 Apr 25. Neuropsychopharmacology. 2008. PMID: 17460614
Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function.
Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F, Poncelet M, Gueudet C, Desvignes C, Le Fur G, Soubrié P. Steinberg R, et al. Among authors: alonso r. J Pharmacol Exp Ther. 2001 Nov;299(2):449-58. J Pharmacol Exp Ther. 2001. PMID: 11602654
Effects of SR140333, a selective non-peptide NK1 receptor antagonist, on trigemino-thalamic nociceptive pathways in the rat.
Michaud JC, Alonso R, Gueudet C, Fournier M, Calassi R, Brelière JC, Le Fur G, Soubrié P. Michaud JC, et al. Among authors: alonso r. Fundam Clin Pharmacol. 1998;12(1):88-94. doi: 10.1111/j.1472-8206.1998.tb00929.x. Fundam Clin Pharmacol. 1998. PMID: 9523190
Effects of serotonergic denervation on the density and plasticity of brain muscarinic receptors in the rat.
Alonso R, Soubrie P. Alonso R, et al. Synapse. 1991 May;8(1):30-7. doi: 10.1002/syn.890080105. Synapse. 1991. PMID: 1714634
SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.
Bignon E, Alonso R, Arnone M, Boigegrain R, Brodin R, Gueudet C, Héaulme M, Keane P, Landi M, Molimard JC, Olliero D, Poncelet M, Seban E, Simiand J, Soubrié P, Pascal M, Maffrand JP, Le Fur G. Bignon E, et al. Among authors: alonso r. J Pharmacol Exp Ther. 1999 May;289(2):752-61. J Pharmacol Exp Ther. 1999. PMID: 10215649
Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function.
Alonso R, Voutsinos B, Fournier M, Labie C, Steinberg R, Souilhac J, Le Fur G, Soubrié P. Alonso R, et al. Neuroscience. 1999;91(2):607-20. doi: 10.1016/s0306-4522(98)00675-7. Neuroscience. 1999. PMID: 10366018
897 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback